baber/WOPTO huggingface dataset:
Patent NZ-533753-A (NZ)
Title: Multianalyte molecular analysis using application-specific random particle arrays
Inventor: BANERJEE SUKANTA
IPC: C12Q1/68
Filed: 2002-12-27
Abstract: A method for the generation of a library of encoded magnetic particles comprising the steps of: (a) generating a first sub-library of magnetic nanoparticles, (b) generating a second sub-library of encoded particles, (c) providing a coupling site on the magnetic nanoparticles contained in the said first sub-library, (d) bringing into contact said first sub-library with said second sub-library to covalently bind said magnetic nanoparticles to said encoded particles to form said library, and (e) providing a functional site on the encoded magnetic particles contained in said library.
Patent NZ-535227-A (NZ)
Title: Tricyclic n-acyl compounds
Inventor: BUHR WILM
IPC: A61P1/00
Filed: 2003-02-12
Abstract: Disclosed are compounds of formula (1), wherein: R1 is H, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, alkoxy-alkyl, alkoxycarbonyl, alkenyl, alkynyl, fluoro-alkyl or hydroxy-alkyl, R2 is H, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxycarbonyl, hydroxy-alkyl, halogen, alkenyl, alkynyl, fluoro-alkyl or cyanomethyl, R3a is H, halogen, fluoro-alkyl, alkyl, alkenyl, alknyl, alkoxy, carboxyl, alkoxycarbonyl, hydroxy-alkyl, alkoxy-alkyl, alkoxy-alkoxy-alkyl, fluoro-alkoxy-alkyl or -CO-NR31R32, R3b is H, halogen, fluoro-alkyl, alkyl, alkenyl, alkynyl, alkoxy, carboxyl, alkoxycarbonyl, hydroxy-alkyl, alkoxy-alkyl, alkoxy-alkoxy-alkyl, fluoro-alkoxy-alkyl or -CO-NR31R32, R4a is H or R41-O, R5a is H is H and R4b and R5b together are a bond, or R4a is hydroxyl, and R5a, R4b and R5b are H, and Arom is a mono- or bicyclic aromatic radical. The compounds are used as intermediates for preparing active ingredients.
Patent NZ-537744-A (NZ)
Title: Oral dosage forms / tablets comprising liquiflash particles manufactured without floss matrices
Inventor: MEZAACHE NAIMA
IPC: A61K31/426
Filed: 2003-06-23
Abstract: Disclosed is a direct compression quick dissolve oral dosage form optionally comprising a super disintegrant, comprising: (a) a drug-containing microparticle (such as liquiflash particles), and (b) an excipient mass comprising: (i) from 0% to about 2.5% by weight of a super disintegrant; and (ii) at least one of a directly compressible inorganic salt, a cellulose derivative, and a mixture thereof; wherein said oral dosage form is a fast dissolving oral dosage form that dissolves in the mouth in less than about 40 seconds, has a friability of less than about 1%, and is manufactured by direct compression processing, and without floss matrices.
Patent NZ-540392-A (NZ)
Title: Parasiticide composition for controlling parasite infestation in animals
Inventor: LAU KAI KIN
IPC: A61P33/14
Filed: 2005-05-30
Abstract: A water washable parasiticide composition is disclosed which is suitable for use as a pour on composition for controlling parasite infestation on animals such as sheep or cattle, wherein the composition comprises a combination of an insect growth regulator IGR (such as triflumuron, fluazuron, cyromazine or methoprene(, a macrocyclic lactone (such as avermectin, ivermectin, abamectin, doramectin or milbemycins), a surfactant, an organic solvent and optionally a synthetic pyrethroid to provide a broad spectrum of activity against mature/immature lice and helminthes. Water washability is achieved by basing the composition on an organic solvent selected from the group consisting of glycols, glycol ethers, glycol ether acetate, C1-C8 alkyl pyrrolidones, butyrolactones, aliphatic hydrocarbons, aromatic hydrocarbons and mixtures thereof together with a surfactant.
Patent NZ-540506-A (NZ)
Title: Disease treatment via antimicrobial peptide inhibitors
Inventor: HILLMAN YITZCHAK
IPC: A01N43/04
Filed: 2003-12-21
Abstract: Disclosed is the use of an inhibitor selected from a) an antibody or an antibody fragment or a functional fragment selected from a single-chain Fv, an Fab, an Fab' or F(ab')2; b)an anti-LL-37 antibody; c) an anti-human beta-defensin-2 antibody; d) SIC, a secreted protein of Streptococcus pyogenes or a functional fragment thereof; e) F-actin; f) a non-functional topological analogue of an AMP that is a dominant negative of AMP or a portion thereof; g) a polypeptide that competes with the AMPs or portions thereof for cognate cell receptors without inducing disease; h) LL-37 or a cathelicidin analogue of LL-37; i) FALL-39 or an analogue of FALL-39; j) PR-39 or an analogue of PR-39. The use being to reduce the level and/or activity of an antimicrobial peptide (AMP), or AMP like molecule, selected from: k) an alpha-defensin 1 to 6; a beta-defensin 1 to 6; m) a cathelicidin; n) S100 calcium-binding protein selected from the list consisting of S100A7, S100A8 and S100A9; o) neutrophil alpha-defensin; p) a functional portion of any species disclosed in k to o. for the preparation of a pharmaceutical composition useful for the treatment of a condition selected from the list consisting of: a disease associated with inflammation, a malignant tumor, an autoimmune disease, a skin disease, a respiratory disease, a gastrointestinal disease and wound healing.
Patent NZ-543134-A (NZ)
Title: System for electronic payment and monitoring of fees
Inventor: BELL JOHN DAVID
IPC: G07B15/02
Filed: 2002-08-30
Abstract: A system for collecting road user charges is disclosed. A personal device is either connected to a vehicle's odometer or to an internal GPS unit, and is activatable by a user for electronic deduction of a payable fee. The device is in wireless communication with a monitor that confirms activation of the device for fee deduction.
Patent NZ-550928-A (NZ)
Title: Method for making decorated bottle caps with improved mechanical strength and device for implementing said method
Inventor: DE GUERRY JEAN
IPC: C25F1/00
Filed: 2005-05-02
Abstract: A method comprising: a) providing sheet or format metal; b) swaging the metal by means of a swaging lubricant, so as to form a swaged blank (1); c) degreasing the swaged blank so as to typically remove the remains of the swaging lubricant, to form a degreased blank (2) capable of being lacquer coated; d) lacquer coating the degreased blank, the resulting lacquer coated blank (3) being then optionally decorated; e) an optional finishing step. The method is characterized in that during the degreasing at step c), the swaged blank (1) is subjected to an energetic radiation emission treatment of selected intensity and duration to eliminate or decompose the remains of lubricant, the treatment being wholly carried out at a metal temperature less than 150 °C, and for a duration typically less than 1 second, so as to obtain, following the treatment, a surface tension not less than 34 dynes/cm. Also disclosed is a device for implementing the method. The method provides the advantage that the low temperature degreasing preserves the mechanical properties of the metal of the swaged blank.
Patent NZ-552182-A (NZ)
Title: Pharmaceutical composition of piperazine derivatives
Inventor: FANARA DOMENICO
IPC: A61K31/495
Filed: 2005-07-07
Abstract: Disclosed is a liquid pharmaceutical composition comprising an active substance chosen from cetirizine, levocctirizine and efletirizinc, and at least one preservative, wherein the amount of preservative is selected from methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, a mixture of methyl parahydroxybenzoate and ethyl parahydroxybenzoate or propyl parahydroxybenzoate, and a mixture of methyl parahydroxybenzoate and propyl parahydroxybenzoate, and wherein the preservative is between 0 and 1.5mg/ml exclusive of the composition.
Patent NZ-553764-A (NZ)
Title: Open container blank suitable for use in a package for plant seeds
Inventor: EASON ANDREW
Filed: 2006-12-11
Abstract: A package for marketing plant seeds including a closable container for containing potting mix and plant seeds and an open container blank that is formable into an open container for receiving the potting mix and the plant seeds so that the plant seeds may germinate and grow in the open container. The open container blank includes a unitary sheet formed with a plurality of fold lines dividing the unitary sheet into a polygonal shaped base, a plurality of peripheral side wails, a connecting portion and a tab extending from the connecting portion. One of the side walls is adapted to receive and releasably retain the tab when the blank is formed into the open container configuration for releasably retaining the open container blank in the open container configuration.
Patent NZ-555930-A (NZ)
Title: Polyurethane light guides
Inventor: JOSEPH EDMOND KENNETH
IPC: G02B1/04
Filed: 2005-12-16
Abstract: A light guide (1) formed from an unclad flexible polyurethane fibre produces significant side scattering (2) over distances of up to several metres. The polyurethane fibre is in the form of a solid fibre or a tube and may comprise light scattering particles. The polyurethane fibre may comprise a transparent flexible polyurethane UV resistant outer cladding. Embodiments include illuminated shoe laces, a power cord safety indicator, an illuminated dental suction tube and a dental curing tip.
Patent NZ-575088-A (NZ)
Title: Antimicrobial wood preservative composition comprising 4,5-dichloro-2-n-octyl-4-isothiazolin-3-one and a copper compound
Inventor: ASHMORE JOH WILLIAM
IPC: A01N47/18
Filed: 2007-11-15
Abstract: Disclosed is a synergistic antimicrobial composition comprising: (a) monoethanolamine complex of copper (II); and (b) 4,5-dichloro-2-n-octyl-4-isothiazolin-3-one wherein the weight ratio of monoethanolamine complex of copper (II) to 4,5-dich10ro-2-n-octyl-4isothiazolin-3-one is from 1:0.0002 to 1:0.1176 and wherein carboxylic acid and tebuconazole are excluded from the composition. (62) Divided Out of 563458
Patent NZ-575745-A (NZ)
Title: Preparation of azoxystrobin
Inventor: BEVERIDGE GILLIAN
IPC: A01N43/54
Filed: 2007-10-02
Abstract: Disclosed is a process for preparing a compound of formula (I) such as azoxystrobin, which comprises either (a) reacting a compound of formula (II) with 2-cyanophenol, or a salt thereof, in the presence of between 0.1 and 40 mol % of 1,4-diazabicyclo[2.2.2]octane (DABCO), or (b) reacting a compound of the formula (III), with a compound of the formula (IV) or a salt thereof, in the presence of between 0.1 and 40 mol % of 1,4-diazabicyclo[2.2.2]octane; wherein W is the methyl (E)-2-(3-methoxy)acrylate group C(CO2CH3)=CHOCH3 or the methyl 2-(3,3-dimethoxy)propanoate group C(CO2CH3)CH(OCH3)2, or a mixture of the two groups, and wherein 1,4-diazabicyclo[2.2.2]octane is not mixed with the compound of formula (II) or the compound of formula (III) unless (i) 2-cyanophenol or the compound of formula (IV) is present; or (ii) 1,4-diazabicyclo[2.2.2]octane is present as an acid salt or (iii) conditions are such that 1,4-diazabicyclo[2.2.2]octane and the compound of formula (II) or the compound of formula (III) are not able to react with each other; with the proviso that when between 0.1 and 2 mol% 1,4-diazabicyclo[2.2.2]octane is used, the 1,4-diazabicyclo[2.2.2]octane is not added last.
Patent NZ-576473-A (NZ)
Title: Patient transfer sheet with inflatable torso and head support for intubation
Inventor: WEEDLING ROBERT E
IPC: A61G7/057
Filed: 2005-02-24
Abstract: An inflatable device for supporting a patient during endotracheal intubation includes a support to accommodate the whole body of a prone patient, an inflatable torso chamber 74 to be inflated to raise the head end portion of a patient above the legs of the patient, and an expandable pillow 76 on the top surface of the torso chamber with a head chamber independently inflatable from the torso chamber to elevate the patient's head. An air inlet system delivers air to the torso and pillow chambers, and an inflation control system controls the delivery of air independently to the torso and pillow chambers so that both the position of the patient's upper torso and of the patient's head can be adjusted to achieve optimal anatomical alignment of the patient's larynx to facilitate intubation. (62) Divided Out of 549836
Patent NZ-579132-A (NZ)
Title: A sock having warm zone made of thermally conductive yearn
Inventor: LAMBERTZ BODO W
IPC: A43B17/04
Filed: 2008-04-07
Abstract: A thermally conductive sock is disclosed. The sock includes a shaft part and a foot part, the foot part has toe area and a heel area. A tread area is situated between the toe area and the heel area. A warm zone is arranged in the toe area and extends around the foot into the tread area. The warm zone is made of a heat-conducting yarn which in use, conducts heat from an external heat source to the warm zone.
Patent NZ-582249-A (NZ)
Title: Substituted piperazines as cb1 antagonists
Inventor: GILBERT ERIC J
IPC: A61K31/496
Filed: 2008-06-25
Abstract: Disclosed is a piperidine of Formula (I) or a pharmaceutically acceptable salt, thereof, wherein the variables are defined in the specification for treating, reducing, or ameliorating a condition or disease selected from psychic disorders, anxiety, schizophrenia, depression, abuse of psychotropes, substance abuse, substance dependency, alcohol dependency, nicotine dependency, neuropathies, migraine, stress, epilepsy, dyskinesias, Parkinson's disease, amnesia, senile dementia, Alzheimer's disease, eating disorders, type II diabetes, gastrointestinal diseases, vomiting, diarrhea, urinary disorders, infertility disorders, inflammation, infection, cancer, neuroinflammation, atherosclerosis, Guillain-Barr syndrome, viral encephalitis, cerebral vascular incidents, cranial trauma, metabolic syndrome, obesity, waist circumference, abdominal girth, type II diabetes, insulin resistance, hepatic lipidosis, fatty liver disease, neuroinflammatory disorders, cognitive disorders, psychosis, addictive behaviour, gastrointestinal disorders, and cardiovascular conditions.
Patent NZ-583670-A (NZ)
Title: Production of 2s canola protein involving cation exchange
Inventor: SEGALL KEVIN I
IPC: C07K1/18
Filed: 2008-08-01
Abstract: Disclosed is a method of producing substantially pure 2S canola protein, which includes: solubilizing canola proteins from canola oil seed meal using an aqueous saline solution having a salt concentration of 0.25 to 0.35 M and a pH of 5 to 6 to form a canola protein solution, separating the canola protein solution from residual canola oil seed meal, contacting the canola protein solution with a cation-exchange medium at a pH of 5 to 6 to bind the 2S canola protein to the cation-exchange medium in preference to other canola proteins, separating the bound 2S canola protein from unbound canola proteins and impurities, and separating the bound 2S canola protein from the cation-exchange medium.
Patent NZ-588367-A (NZ)
Title: Ketorolac tromethamine compositions for treating or preventing ocular pain
Inventor: FARNES ELDON QUINN
IPC: A61K9/08
Filed: 2009-03-03
Abstract: 588367 Disclosed is a topical aqueous ophthalmic solution comprising 0.45 percent w/v ketorolac tromethamine, about 0.5 percent w/v carboxymethyl cellulose and no preservative.
Patent NZ-588533-A (NZ)
Title: Multifocal pupil size responsive refractive and diffractive ophthalmic and intraocular lens
Inventor: SIMPSON MICHAEL J
IPC: G02C7/06
Filed: 2008-10-02
Abstract: An intraocular lens (IOL) (10), comprising an optic having an anterior surface and a posterior surface, the optic having a central refractive region (18) for providing one refractive focusing power, and a diffractive region (20) disposed on one of the surfaces so as to provide a near and a far diffractive focusing powers. The IOL is sized so that at a first pupil size the IOL is a monofocal lens having a focusing power corresponding to the refractive focusing power provided by the central refractive region and as pupil size increases the IOL is a multi focal IOL with the diffractive region focusing varying amounts of light energy to the near and far diffractive focusing powers.
Patent NZ-591311-A (NZ)
Title: Treatment of acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct
Inventor: ZUGMAIER GERHARD
IPC: C07K16/28
Filed: 2009-11-06
Abstract: Disclosed is the use of a CD19xCD3 bispecific single chain antibody construct for the manufacture of a medicament for the treatment, amelioration or elimination of acute lymphoblastic leukemia (ALL).
Patent NZ-593220-A (NZ)
Title: Immunostimulatory oligonucleotides
Inventor: DAVIS HEATHER LYNN
IPC: A61K39/00
Filed: 2009-12-01
Abstract: Provided is an immunostimulatory oligonucleotide comprising the nucleotide sequence 5' TCGTCGTTTTTCGGTGCTTTT 3' (SEQ ID NO: 1), which may comprise one or more modified linkages. The oligonucleotide may be formulated into a vaccine together with a microbial, viral or parasitic antigen. The bacterial antigen may be from dental caries causing Streptococcus species.
Patent NZ-595318-A (NZ)
Title: Automated carcass portion butchering techniques and apparatus
Inventor: FERN STEVEN
IPC: A22C18/00
Filed: 2009-04-03
Abstract: A method of performing a longitudinal cut along a saddle section (59) of a carcass including the steps of: a) locating a pair of spaced apart tines (52, 53) in one end of a spinal column of the saddle section; and b) moving the saddle section relative to a cutting tool (60) to cut longitudinally through the spinal column to cut the saddle section in half with the cutting tool passing between the pair of spaced apart tines. An apparatus for performing the method is also disclosed.
Patent NZ-595438-A (NZ)
Title: Plasterboard jointing system comprising a fibrous connective material and joint filling and finishing compounds
Inventor: THOMPSON BILL
IPC: C04B14/22
Filed: 2010-02-23
Abstract: 595438 A system of jointing and finishing plasterboard sheets. The system comprises adjacently abutted first and second plasterboard sheets and a connective material. The connective material is applied to a region at or near the side edge portions of the first and second plasterboard sheets and which securely joins the side edge portion of the first plasterboard sheet to the side edge portion of the second plasterboard sheet. There is also provided a joint filling compound and a finishing compound, which is applied to the region of the first and second plasterboard sheets. A chemical agent is applied in the region of the first and second plasterboard sheets or impregnated into the connective material that catalyses the curing/setting reaction of the joint filling compound.
Patent NZ-597369-A (NZ)
Title: Optical system for direct imaging of light markable material
Inventor: TAMKIN JOHN MICHAEL
IPC: B23K26/18
Filed: 2009-06-03
Abstract: 597369 Imaging systems for writing information on a light-sensitive label are disclosed. The systems comprise an array (90) of light sources (100), which may be lasers, and an array (105) of lenses (107) corresponding to the light sources for directing the light sources. The array of lenses may direct the respective light beams (104) toward an image plane, or may have substantially parallel optical axes. A labelling apparatus (see 40, figure 1) may be provided for positioning the light-senstive label at an image plane. An optical relay, which may be afocal, and which may have an optical axis substantially parallel to the optical axes of the lenses, may also be included. The optical relay (see 300, figure 15) also may have a reflective surface. The optical relay may produce a magnified image of the light beams on the light-sensitive label and thereby write a pattern thereon. Methods of imaging and methods of writing information on a light sensitive label are also provided.
Patent NZ-600793-A (NZ)
Title: Mask and components thereof
Inventor: BERTHON-JONES MICHAEL
IPC: A61M16/06
Filed: 2003-11-06
Abstract: 600793 A mask assembly for the application of non-invasive positive pressure ventilation to a patient, comprising: a frame including a main body including at least one aperture configured to receive a supply of breathable gas under pressure, and a cushion assembly (600) provided to the frame. The cushion assembly is structured to provide an interface with the patient, and includes a flexible element (630) to conform against the face of patient when in use. The flexible element comprises at least first (631) and second portions (632) of foam, the first portion having a first stiffness and the second portion having a second stiffness. The first stiffness is less than the second stiffness.
Patent NZ-605403-A (NZ)
Title: Method of producing recombinant adamts13 in cell culture
Inventor: GRILLBERGER LEOPOLD
IPC: C12N9/48
Filed: 2011-07-08
Abstract: Discloses a method of producing a recombinant ADAMTS13 (rA13) composition, the method comprising (a) providing a basal cell culture media; (b) supplementing the basal cell culture media with copper to provide a supplemented basal cell culture media with a final copper concentration of from 1.0 ug/L to 20 ug/L; (c) providing one or more cells comprising a nucleic acid encoding a rA13 protein; (d) culturing the one or more cells in the supplemented basal cell culture media such that the rA13 protein is expressed and excreted from the cells into a cell culture supernatant, wherein the NH4 + content of the cell culture supernatant is maintained at a concentration below 10 mM; and (e) recovering at least a portion of the cell culture supernatant, wherein at least 1500 Units FRETS-VWF73 activity per litre of the supplemented basal cell culture media per day is present in the cell culture supernatant recovered.
Patent NZ-608489-A (NZ)
Title: Citrullinated peptides for diagnosing and prognosing rheumatiod arthritis
Inventor: LING NICHOLAS CHI-KWAN
IPC: C07K1/107
Filed: 2010-03-26
Abstract: Disclosed is a method for identifying a peptide that is immunologically reactive with an anticitrullinated protein antibody, said method comprising: (a) identifying at least one antigenic peptide epitope in at least one synovial fluid polypeptide, wherein said antigenic peptide epitope is predicted to be immunologically reactive with an anti-citrullinated protein antibody, wherein said antigenic peptide epitope contains at least one arginine residue, and wherein at least one of said arginine residues is citrullinated; (b) synthesising a peptide that comprises at least two of said antigenic peptide epitopes, wherein said antigenic peptide epitopes are linked together by a peptide bond; (c) contacting a biological sample from an individual having rheumatoid arthritis (RA) with said peptide under conditions suitable to transform said peptide into a complex comprising said peptide and said anti-citrullinated protein antibody; and (d) identifying said peptide as being immunologically reactive with said anticitrullinated protein antibody based on the presence or level of said complex.
Patent NZ-609804-A (NZ)
Title: Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
Inventor: FATHEREE PAUL R
IPC: C07D233/70
Filed: 2011-11-09
Abstract: The disclosure relates to crystalline salt forms, namely the hemi-edisylate and hemi-napadisylate forms of 4’-{ 2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl} -3’-fluorobiphenyl-2-carboxylic acid. The disclosure also relates to pharmaceutical compositions comprising these crystalline forms, methods for forming them and methods of using the crystalline forms in medicaments for the treatment of diseases such as heart disease or hypertension.